Titan Pharmaceuticals, Inc. (TTNP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.3300 |
| Open | 1.3400 |
| Bid | 1.3800 x 900 |
| Ask | 1.4400 x 1100 |
| Day's Range | 1.3400 - 1.4499 |
| 52 Week Range | 0.3500 - 2.3800 |
| Volume | |
| Avg. Volume | 767,435 |
| Market Cap | 20.335M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8650 |
| Earnings Date | Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TTNP
Related Research
- Titan Pharmaceuticals, Inc.Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.RatingFair ValueEconomic Moat3 days agoArgus Research
- GlobeNewswire
Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) with 25.2% of the Company’s outstanding shares, today issued the following statement: “We have submitted a request for the Company to hold a special meeting of the Company’s stockholders (the “Special Meeting”) to expand th
- Simply Wall St.
Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- PR Newswire
Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for a Phase 1 study of its six-month or longer subdermal formulation of nalmefene, an opioid antagonist, intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder ("OUD").
